[go: up one dir, main page]

WO2013181384A1 - Formes à l'état solide d'aleglitazar sodique - Google Patents

Formes à l'état solide d'aleglitazar sodique Download PDF

Info

Publication number
WO2013181384A1
WO2013181384A1 PCT/US2013/043354 US2013043354W WO2013181384A1 WO 2013181384 A1 WO2013181384 A1 WO 2013181384A1 US 2013043354 W US2013043354 W US 2013043354W WO 2013181384 A1 WO2013181384 A1 WO 2013181384A1
Authority
WO
WIPO (PCT)
Prior art keywords
aleglitazar
sodium
crystalline
degrees
solid state
Prior art date
Application number
PCT/US2013/043354
Other languages
English (en)
Inventor
Alexandre Mathieu
Wolfgang Albrecht
Jens Geier
Original Assignee
Ratiopharm Gmbh
Teva Pharmaceuticals Usa, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ratiopharm Gmbh, Teva Pharmaceuticals Usa, Inc. filed Critical Ratiopharm Gmbh
Publication of WO2013181384A1 publication Critical patent/WO2013181384A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Definitions

  • the invention relates to solid state forms of Aleglitazar sodium, processes for preparing the solid state forms, and pharmaceutical compositions comprising said solid state forms.
  • Aleglitazar is reported to be a peroxisome proliferator-activated receptor agonist with affinity to PPARa and PPARy, developed by Hoffmann-La Roche.
  • Publication WO2010084066 describes a composition comprising Aleglitazar or Aleglitazar sodium.
  • Polymorphism the occurrence of different crystal forms, is a property of some molecules and molecular complexes.
  • a single compound may give rise to a variety of polymorphs having distinct crystal structures and physical properties like melting point, thermal behaviors (e.g., measured by thermogravimetric analysis - "TGA”, or differential scanning calorimetry - “DSC”), powder X-ray diffraction (XRD) pattern, infrared or Raman absorption fingerprint, and solid state NMR spectrum.
  • TGA thermogravimetric analysis -
  • DSC differential scanning calorimetry -
  • Discovering new polymorphic forms and solvates of a pharmaceutical product can provide materials having desirable processing properties, such as ease of handling, ease of processing, storage stability, and ease of purification or as desirable intermediate crystal forms that facilitate conversion to other polymorphic forms.
  • New polymorphic forms and solvates of a pharmaceutically useful compound or salts thereof can also provide an opportunity to improve the performance characteristics of a pharmaceutical product. It enlarges the repertoire of materials that a formulation scientist has available for formulation optimization, for example by providing a product with different properties, e.g., better processing or handling characteristics, improved dissolution profile, or improved shelf-life. For at least these reasons, there is a need for additional polymorphs of Aleglitazar and salts thereof.
  • the present invention provides new solid state forms of Aleglitazar sodium. These solid state forms can be used to prepare pharmaceutical compositions and formulations comprising said solid state forms of Aleglitazar sodium.
  • the present invention also provides pharmaceutical compositions comprising one or more of the solid state forms of Aleglitazar sodium of the present invention.
  • the invention also provides the use of the solid state forms of Aleglitazar sodium described herein for the preparation of Aleglitazar free acid, or different salts of Aleglitazar.
  • the present invention encompasses the use of the above described crystalline form of Aleglitazar sodium for the preparation of pharmaceutical compositions.
  • the present invention encompasses pharmaceutical formulations comprising one or more of the solid state forms of Aleglitazar sodium of the present invention, or comprising a pharmaceutical composition comprising the above described solid state forms of Aleglitazar sodium, and at least one pharmaceutically acceptable excipient.
  • the present invention encompasses a process for preparing the above mentioned pharmaceutical formulations. The process comprises combining one or more of the solid state forms of Aleglitazar sodium of the present invention, or the pharmaceutical composition comprising the above described solid state forms of Aleglitazar sodium, with at least one pharmaceutically acceptable excipient.
  • the crystalline forms as defined herein as well as the pharmaceutical compositions and formulations of said one or more solid state forms of Aleglitazar sodium can be used as medicaments, particularly for the treatment of hyperglycemia and dyslipidemia in patients with type 2 diabetes.
  • the present invention also provides a method of treating hyperglycemia and dyslipidemia in patients with type 2 diabetes, comprising administering a therapeutically effective amount of one or more of the solid state forms of Aleglitazar sodium of the present invention, or one of the above pharmaceutical compositions or formulations, to a subject suffering from hyperglycemia and dyslipidemia in patients with type 2 diabetes, or otherwise in need of the treatment.
  • the present invention also provides the use of the Aleglitazar sodium and solid state forms thereof of the present invention, or at least one of the above pharmaceutical compositions and formulations for the manufacture of a medicament for treating
  • Figure 1 provides a powder XRD pattern of crystalline Form A of Aleglitazar sodium.
  • Figure 2 provides a differential scanning calorimetric (DSC) thermogram of crystalline Form A of Aleglitazar sodium.
  • Figure 3 provides a powder XRD pattern of crystalline Form B of Aleglitazar sodium.
  • Figure 4 provides a differential scanning calorimetric (DSC) thermogram of crystalline Form B of Aleglitazar sodium.
  • Figure 5 provides a powder XRD pattern of crystalline Form C of Aleglitazar sodium.
  • Figure 6 provides a differential scanning calorimetric (DSC) thermogram of crystalline Form C of Aleglitazar sodium.
  • Figure 7 provides a Raman spectrum of crystalline Form C of Aleglitazar sodium.
  • Figure 8 provides a Raman spectrum of crystalline Form B of Aleglitazar sodium.
  • Figure 9 provides a C NMR spectrum of crystalline Form C of Aleglitazar sodium (in the 0-240 ppm range).
  • Figure 10 provides a C NMR spectrum of crystalline Form B of Aleglitazar sodium (in the 0-240 ppm range).
  • the present application relates to crystalline Aleglitazar sodium, including three particular crystalline forms of Aleglitazar sodium, as well as pharmaceutical compositions and formulations comprising said crystalline Aleglitazar sodium.
  • the solid state forms of the Aleglitazar sodium according to the present invention have advantageous properties selected from at least one of the following: chemical purity, flowability, filterability, compressibility, solubility, morphology or crystal habit, bulk/tap density, stability, such as storage stability, stability to dehydration, stability to polymorphic conversion, low hygroscopicity, and low content of residual solvents.
  • Form C is particularly advantageous, for example, in being polymorphic and chemically stable under different relative humidity levels. For example, when stored for 7 days at 40°C under 75% relative humidity, no polymorphic transformation is observed.
  • Form C is also freely soluble (> 100 mg/mL) in water and phosphate buffer.
  • a crystal form may be referred to herein as substantially free of any other solid forms.
  • the expression “substantially free” will be understood to mean that the crystalline form contains 20% or less, 10%> or less, 5% or less, 2%> or less, or 1% or less of any other solid form of the subject compound as measured, for example, by powder X-ray diffraction (PXRD).
  • polymorphs of Aleglitazar sodium described herein as substantially free of any other solid forms would be understood to contain greater than 80% (w/w), greater than 90% (w/w), greater than 95% (w/w), greater than 98% (w/w), or greater than 99% (w/w) of the subject form of Aleglitazar sodium.
  • the described polymorphs of the Aleglitazar sodium may contain from 1% to 20% (w/w), from 5% to 20% (w/w), or from 5% to 10% (w/w) of one or more other solid forms of Aleglitazar sodium.
  • a solid state form may be referred to herein as being characterized by graphical data "as shown in” or “as depicted in” a Figure.
  • Such data include, for example, powder X- ray diffractograms and solid state NMR spectra.
  • the graphical data potentially provides additional technical information to further define the respective solid state form (a so-called "fingerprint") which can not necessarily be described by reference to numerical values or peak positions alone.
  • the skilled person will understand that such graphical representations of data may be subject to small variations, e.g., in peak relative intensities and peak positions due to factors such as variations in instrument response and variations in sample concentration and purity, which factors are well known to the skilled person.
  • a solid state form may be referred to herein as being characterized by data selected from two or more different data groupings, for example, by a powder XRD pattern having a group of specific peaks; or by a powder XRD pattern as shown in a figure depicting a diffractogram, or by "a combination thereof (or “combinations thereof,” or "any
  • any combination thereof contemplate that the skilled person may characterize a crystal form using a combination of characteristic analytical data.
  • the skilled person may characterize a crystal form using a group of four or five characteristic powder XRD peaks, and supplement that characterization with an additional feature observed in the powder X-ray diffractogram, e.g., an additional peak, a characteristic peak shape, a peak intensity, or even the absence of a peak at some position in the powder XRD pattern.
  • anhydrous in relation to any of the crystalline Aleglitazar sodium salts relates to a crystalline Aleglitazar sodium salt which contains not more than 1% (w/w) of either water or organic solvents (bound and unbound) as measured by TGA or by Karl Fischer titration.
  • solvate refers to a crystal form that incorporates a solvent in the crystal structure.
  • the solvent is water, the solvate is often referred to as a "hydrate.”
  • the solvent in a solvate may be present in either a stoichiometric or in a non-stoichiometric amount.
  • a thing e.g., a reaction mixture
  • room temperature often abbreviated "RT.” This means that the temperature of the thing is close to, or the same as, that of the space, e.g., the room or fume hood, in which the thing is located.
  • room temperature is from about 20°C to about 30°C, or about 22°C to about 27°C, or about 25°C.
  • the present invention provides crystalline Aleglitazar sodium.
  • the present invention further provides a crystalline form of Aleglitazar sodium, designated Form A.
  • Form A can be a hydrate form.
  • Form A may contain from about 3.5%, to about 15% water, for example, about 6.8%> water.
  • Form A can be characterized by data selected from one or more of the following: a powder XRD pattern having peaks at 2.4, 6.4, 12.0, 12.8, 15.8, 16.9, and 26.7 degrees 2 ⁇ ⁇ 0.2 degrees 2 ⁇ ; a powder XRD pattern as shown in figure I; a DSC thermogram as shown in figure 2; and any combinations of these data.
  • Crystalline Form A may be further characterized by a powder XRD pattern having additional peaks at 4.8, 14.4, 14.9, 22.5, and 26.4 degrees 2 ⁇ ⁇ 0.2 degrees 2 ⁇ .
  • Form A may be characterized by each of the above characteristics alone and/or by all possible combinations, e.g. by a powder XRD diffraction pattern having peaks at 2.4, 6.4, 12.0, 12.8, 15.8, 16.9, and 26.7 degrees 2 ⁇ ⁇ 0.2 degrees 2 ⁇ and a powder XRD pattern as shown in figure 1 , or by peaks in a powder XRD diffraction pattern and combined with a peak in a DSC thermogram.
  • Form A can be obtained by a process comprising crystallizing Aleglitazar sodium from a mixture of THF, acetonitrile and ethanol.
  • the present invention also provides a crystalline Aleglitazar sodium, designated Form B.
  • Form B can be an anhydrous Form.
  • Form B can be characterized by data selected from: a powder XRD pattern having peaks at 4.7, 14.5, 19.3, 21.5, and 23.3 degrees 2 ⁇ ⁇ 0.2 degrees 2 ⁇ ; a powder XRD pattern as
  • Form B may be further characterized by a powder XRD pattern having peaks at 5.3, 7.8, 8.7, 13.7, and 17.5 degrees 2 ⁇ ⁇ 0.2 degrees 2 ⁇ .
  • Form B can be further characterized by data selected from one or more of the following: a Raman spectrum having characteristic peaks at 1633, 1187, 1067, 1015, and 524 ⁇ 4 cm “1 ; a Raman spectrum as depicted in figure 8; a DSC thermogram as shown in figure 4.
  • Form B may be characterized by each of the above characteristics alone and/or by all possible combinations, e.g. by a powder XRD diffraction pattern having peaks at 4.7, 14.5, 19.3, 21.5, and 23.3 degrees 2 ⁇ ⁇ 0.2 degrees 2 ⁇ and a powder XRD pattern as shown in figure 3, or by peaks in a powder XRD diffraction pattern combined with a peak in a DSC thermogram or certain peaks in a solid state NMR spectrum.
  • Form B can be prepared, for example, by heating Form A or Form C to 140°C to 170°C.
  • the present invention further provides a crystalline form of Aleglitazar sodium, designated Form C.
  • Form C can be a hydrate form.
  • Form C may contain from about 3.5%, to about 15% water, for example, about 6.8% water.
  • Form C can contain from about 5.7 to about 6%) water.
  • Form C can be characterized by data selected from one or more of the following: a powder XRD pattern having peaks at 2.4, 4.8, 7.2, 12.0, and 16,8 degrees 2 ⁇ ⁇ 0.2 degrees 2 ⁇ , and not having a peak at 6.4 degrees 2 ⁇ ⁇ 0.2 degrees 2 ⁇ ; a powder XRD pattern as
  • Crystalline Form C may be further characterized by a powder XRD pattern having additional peaks at 12.7, 14.4, 15.7, 20.2, and 24.1 degrees 2 ⁇ ⁇ 0.2 degrees 2 ⁇ ; a Raman spectrum having characteristic peaks at 1642, 1554, 1335, 538, and 315 ⁇ 4 cm “1 ; a Raman spectrum as depicted in figure 7; a DSC thermogram as shown in figure 6; and by
  • Form C may be characterized by each of the above characteristics alone and/or by all possible combinations, e.g. by a powder XRD diffraction pattern having peaks at 2.4, 4.8, 7.2, 12.0, 12.7, 14.4, 15.7, 16.8, 20.2, and 24.1 degrees 2 ⁇ ⁇ 0.2 degrees 2 ⁇ and a powder XRD pattern as shown in figure 5, or by peaks in a powder XRD diffraction pattern and combined with a peak in a DSC thermogram or certain peaks in a solid state NMR spectrum.
  • a powder XRD diffraction pattern having peaks at 2.4, 4.8, 7.2, 12.0, 12.7, 14.4, 15.7, 16.8, 20.2, and 24.1 degrees 2 ⁇ ⁇ 0.2 degrees 2 ⁇ and a powder XRD pattern as shown in figure 5, or by peaks in a powder XRD diffraction pattern and combined with a peak in a DSC thermogram or certain peaks in a solid state NMR spectrum.
  • Form C can be obtained by a process comprising crystallizing Aleglitazar sodium from water.
  • the above solid state forms can be used to prepare a pharmaceutical composition comprising any one or more of the above mentioned forms, as well as formulations further comprising at least one pharmaceutical acceptable excipient.
  • a pharmaceutical composition comprising any one or more of the above mentioned forms, as well as formulations further comprising at least one pharmaceutical acceptable excipient.
  • the solid state forms described herein contain 20% or less, for example 10%> or less, or 5% or less, or 2% or less, or 1% or less of any other crystalline form of the respective Aleglitazar sodium.
  • the present invention further encompasses a pharmaceutical composition comprising any one or combination of solid state forms, as described above.
  • the invention also encompasses pharmaceutical formulations comprising any one or combination of the solid state forms described herein, and at least one pharmaceutically acceptable excipient.
  • the invention also encompasses a process for preparing a pharmaceutical formulation comprising combining any one or more of the above mentioned forms, and at least one pharmaceutical acceptable excipient.
  • the solid state forms as described herein can be used to prepare Aleglitazar free acid, for example, by reacting the above mentioned forms with an acid.
  • the solid state forms as described herein can be used to prepare a different salt of Aleglitazar, for example by reacting said forms with an acid producing Aleglitazar free acid, and further reacting the product with a different base, providing a new salt of Aleglitazar.
  • the starting Aleglitazar sodium forms can react with another base having a pKa higher than the pKa of the starting sodium base, i.e., salt switching.
  • the invention also encompasses a process for converting the solid state forms as described herein to Aleglitazar free acid, for example, by reacting the above mentioned forms with an acid.
  • the above mentioned forms are formed by the processes described in the present invention.
  • the invention also encompasses a process for preparing a different salt of
  • Aleglitazar comprising reacting the solid state forms as described herein with an acid producing Aleglitazar free acid, and further reacting the product with a different base, providing a new salt of Aleglitazar.
  • the above mentioned forms are formed by the processes described in the present invention.
  • the invention also encompasses a process for preparing a different salt of
  • Aleglitazar comprising reacting the starting Aleglitazar sodium forms according to the present invention with another base having a pKa higher than the pKa of the starting sodium base.
  • the above mentioned forms are formed by the processes described in the present invention.
  • the present invention also provides solid state forms as described herein for use as a medicament.
  • the medicaments can be used for the treatment of hyperglycemia and dyslipidemia in patients with type 2 diabetes.
  • Raman spectra were measured on a Senterra Raman microscope (Bruker Optics) at 785 nm (100 mW) using a 50x objective (laser beam diameter approx. 2 ⁇ ) and a slit type aperture (50 x 1000 um) in high resolution mode (3 - 5 cm "1 ). 2 scans with an integration time of 2 s were added.
  • the beaker was placed in an autoclave. Air was evacuated and hydrogen was introduced to achieve 40 bar at 80°C. After 16 h, HPLC analysis of a control sample verified that the hydrogenation was completed. Thereafter, the reaction mixture was transferred into a 500 ml round bottom flask, the solvent was evaporated and 70 ml 1 N NaOH and 150 ml tert. -butyl methyl ether were added. The suspension was stirred for 15 min and transferred into a separation funnel and 20 ml water were added. The aqueous phase was separated, acidified with IN HC1 (pH ⁇ 2) and extracted with 300 ml ethyl acetate.
  • Step 1 The material of Step 1 was dissolved in 40 ml tetrahydrofuran (THF) and heated to reflux. 18 mmol (S)-phenylethylamine, dissolved in 4.5 ml THF were added, the mixture was allowed to cool to RT and a spatula of (20 mg) solid (S)-phenylethylamine salt of (S)-2- methoxy-3- ⁇ 4-[2-(5-methyl-2-phenyl-oxazol-4-yl)-ethoxy]-benzo[b]thiophen-7-yl ⁇ -propionic acid was added. The product started to precipitate and was filtered off and washed with THF.
  • THF tetrahydrofuran
  • (S)-phenylethylamine salt of (S)-2-methoxy-3- ⁇ 4-[2-(5-methyl-2-phenyl-oxazol-4- yl)-ethoxy]-benzo[b]thiophen-7-yl ⁇ -propionic acid (4 g) was suspended in 43 ml ethyl acetate. To the suspension, 4.7 ml IN HC1 and 10 ml water were added and the biphasic mixture was stirred at r.t. for 1 h. The organic phase was separated and the aqueous phase extracted with 20 ml ethyl acetate. The organic fractions were combined, dried over sodium sulfate and filtered.
  • Aleglitazar (3 g) was dissolved in 34 mL THF at RT. To this solution, 0.90 mL NaOH (32%) was added. After addition of acetonitrile (7 mL in one portion at RT) the reaction mixture was one block [ including the solvent], which was dissolved in ethanol. Evaporation of ethanol at 40°C on a rotary evaporator led to a yellow solid which was sonicated in pentane for 10 minutes. The resulting white solid was filtered and dried at room temperature for 1 hour, yielding 2.7 g of Aleglitazar sodium, Form A.
  • Aleglitazar 38.3 g was suspended in ethanol (800 mL) and heated at reflux temperature. To the clear solution sodium hydroxide (32% aqueous solution, 10.94 mL) was added. The mixture was cooled to room temperature under stirring and the solvent was removed on a rotary evaporator. The residue was triturated under pentane (300 mL). The contained solid was isolated by filtration and dried at 40°C /20 mbar to yield 37.6 g of Aleglitazar sodium.
  • Aleglitazar sodium was purified by removal of methanol-insoluble compounds before use: [0077] Aleglitazar sodium (6.5 g) was dissolved in MeOH (60 mL) at room temperature. The turbid grey-coloured solution was filtered through a folded filter, resulting in a clear yellow solution. The solvent was evaporated at 40°C /160 mbar (rotary evaporator). A yellow syrup remained, which crystallized within 1 day at room temperature. The product was dried at 44°C /20 mbar for 12h to yield 5.9 g of Aleglitazar sodium as colourless powder
  • Form C of Aleglitazar sodium (2.0 g) was heated at 170°C in a drying apparatus (drying agent: CaCl 2 ; static vacuum generated by membrane pump) for lh.
  • Form B was obtained as an almost colourless powder (1.9 g). No melting was observed during heating.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne des formes à l'état solide d'Aleglitazar sodique, des procédés pour la préparation des formes à l'état solide et des compositions pharmaceutiques comprenant les formes à l'état solide.
PCT/US2013/043354 2012-05-31 2013-05-30 Formes à l'état solide d'aleglitazar sodique WO2013181384A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261653799P 2012-05-31 2012-05-31
US61/653,799 2012-05-31

Publications (1)

Publication Number Publication Date
WO2013181384A1 true WO2013181384A1 (fr) 2013-12-05

Family

ID=48577958

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2013/043354 WO2013181384A1 (fr) 2012-05-31 2013-05-30 Formes à l'état solide d'aleglitazar sodique

Country Status (1)

Country Link
WO (1) WO2013181384A1 (fr)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002092084A1 (fr) 2001-05-15 2002-11-21 F. Hoffmann-La Roche Ag Derives d'oxazole substitues par de l'acide carboxylique utiles en tant qu'activateurs ppar-alpha et gamma dans le traitement du diabete
WO2005030764A1 (fr) 2003-09-29 2005-04-07 F. Hoffmann-La Roche Ag Procede de preparation de derives chiraux de l'acide propionique
WO2010084066A1 (fr) 2009-01-23 2010-07-29 F. Hoffmann-La Roche Ag Composition pharmaceutique comprenant de l'aleglitazar
WO2010108861A1 (fr) 2009-03-24 2010-09-30 F. Hoffmann-La Roche Ag Procédé de préparation de dérivés de l'acide propionique
WO2011070179A1 (fr) 2009-12-07 2011-06-16 F. Hoffmann-La Roche Ag Procédé pour la préparation de dérivés d'acide propionique

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002092084A1 (fr) 2001-05-15 2002-11-21 F. Hoffmann-La Roche Ag Derives d'oxazole substitues par de l'acide carboxylique utiles en tant qu'activateurs ppar-alpha et gamma dans le traitement du diabete
WO2005030764A1 (fr) 2003-09-29 2005-04-07 F. Hoffmann-La Roche Ag Procede de preparation de derives chiraux de l'acide propionique
WO2010084066A1 (fr) 2009-01-23 2010-07-29 F. Hoffmann-La Roche Ag Composition pharmaceutique comprenant de l'aleglitazar
WO2010108861A1 (fr) 2009-03-24 2010-09-30 F. Hoffmann-La Roche Ag Procédé de préparation de dérivés de l'acide propionique
WO2011070179A1 (fr) 2009-12-07 2011-06-16 F. Hoffmann-La Roche Ag Procédé pour la préparation de dérivés d'acide propionique

Similar Documents

Publication Publication Date Title
EP2571863B1 (fr) Sels de nilotinib et leurs formes cristallines
EP2603503B1 (fr) Mésylate de dabigatran étexilate, ses formes solides et leurs procédés de préparation
US20170305936A1 (en) Solid state forms of crisaborole
CN105209437A (zh) 心肌肌球蛋白激动剂的盐和制备盐的方法
WO2012027543A1 (fr) Formes solides de dabigatran étexilate et de dabigatran étexilate mésylate et leurs méthodes de préparation
US9856270B2 (en) Dolutegravir salts
US9221815B2 (en) Solid state form of vemurafenib choline salt
WO2015103456A1 (fr) Formes cristallines de di-maléate d'afatinib
JP6816036B2 (ja) ヒストン脱アセチル化阻害剤の結晶形態
US10640487B2 (en) Solid state forms of Nilotinib salts
CA2900951A1 (fr) Formes solides de chlorhydrate de vemurafenib
AU2016304852B2 (en) Processes for preparing an FGFR inhibitor
EP3398946B1 (fr) Sel de dérivé de morpholine et sa forme cristalline, et procédé de préparation, composition pharmaceutique et utilisation de ce dernier
US11407759B2 (en) Solid forms of 3-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-[1,3]dioxolo[4,5-f]indol-7-yl)pyrrole-2,5-dione
WO2012071425A1 (fr) Formes à l'état solide de bésylate de sorafénib et procédés de préparation
WO2016172333A1 (fr) Forme à l'état solide de pérampanel
WO2013181251A9 (fr) Sel de chlorhydrate de crizotinib sous forme cristalline
WO2012125993A1 (fr) Formes à l'état solide de base rilpivirine et sels de rilpivirine
WO2013181384A1 (fr) Formes à l'état solide d'aleglitazar sodique
KR20120053027A (ko) 페소테로딘 푸마레이트 및 페소테로딘 염기의 결정형
US20220372006A1 (en) Solid state forms of pemafibrate
WO2019099761A1 (fr) Formes à l'état solide d'elafibranor
WO2016081538A1 (fr) Formes solides de ceritinib et sels de ceux-ci
WO2017035170A1 (fr) Formes à l'état solide de maléate de cédiranib
WO2012177708A1 (fr) Oléate de palipéridone

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13727789

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 13727789

Country of ref document: EP

Kind code of ref document: A1